Boehringer Ingelheim, Sanofi to Produce Biopharmaceuticals

Jan. 19, 2015

Boehringer Ingelheim and Sanofi announced a strategic alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies, according to a press release. Boehringer Ingelheim’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline.

Under the terms of the agreement Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin in early 2015 per the press release.